"Drug Eruptions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.
| Descriptor ID |
D003875
|
| MeSH Number(s) |
C17.800.174.600 C20.543.206.380 C25.100.468.380
|
| Concept/Terms |
Drug Eruptions- Drug Eruptions
- Drug Eruption
- Eruption, Drug
- Eruptions, Drug
- Dermatitis Medicamentosa
- Dermatitis, Adverse Drug Reaction
Morbilliform Drug Reaction- Morbilliform Drug Reaction
- Drug Reaction, Morbilliform
- Drug Reactions, Morbilliform
- Morbilliform Drug Reactions
- Reaction, Morbilliform Drug
- Reactions, Morbilliform Drug
- Maculopapular Exanthem
- Exanthem, Maculopapular
- Exanthems, Maculopapular
- Maculopapular Exanthems
- Morbilliform Exanthem
- Exanthem, Morbilliform
- Exanthems, Morbilliform
- Morbilliform Exanthems
- Maculopapular Drug Eruption
- Drug Eruption, Maculopapular
- Drug Eruptions, Maculopapular
- Eruption, Maculopapular Drug
- Eruptions, Maculopapular Drug
- Maculopapular Drug Eruptions
|
Below are MeSH descriptors whose meaning is more general than "Drug Eruptions".
Below are MeSH descriptors whose meaning is more specific than "Drug Eruptions".
This graph shows the total number of publications written about "Drug Eruptions" by people in this website by year, and whether "Drug Eruptions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Eruptions" by people in Profiles.
-
Severe cutaneous adverse reactions: comparing outcomes in children with and without complex chronic conditions. J Allergy Clin Immunol Pract. 2020 Feb; 8(2):790-792.e3.
-
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.
-
Raltegravir-induced drug reaction with eosinophilia and systemic symptoms syndrome in a child. Ann Allergy Asthma Immunol. 2016 Dec; 117(6):719-721.
-
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117.
-
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
-
Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305.
-
Drug-associated lymphoma and pseudolymphoma: recognition and management. Dermatol Clin. 2007 Apr; 25(2):233-44, vii.
-
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006 Oct; 16(5):525-40.
-
Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 1996 Feb; 39(2):257-65.
-
Morphea after bromocriptine therapy. Int J Dermatol. 1989 Apr; 28(3):177-9.